Roivant Sciences is trading at $36.68, up 5.04%, after brepocitinib met primary endpoints in both Phase 3 CLARITY trials for non-infectious uveitis. - At Week 48, 62% of treated patients achieved steroid-free quiescence versus 20% on placebo; key secondary endpoints also showed significant benefit. - The company plans to file a supplemental New Drug Application in the first half of 2027. - Coverage said shares rose nearly 9% in premarket trading; live volume was not provided.